Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories Inc. – IPXL

NEW YORK, NY / ACCESSWIRE / November 9, 2016 / Pomerantz LLP is investigating claims on behalf of investors of Impax Laboratories Inc. (“Impax” or the “Company”) (NASDAQ: IPXL) (ISIN: US9841211033). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Impax and certain of its officers and/or directors have violated the federal securities laws.

[Click here to join a class action]

On November 3, 2016, media outlets reported that United States prosecutors may file criminal charges by the end of 2016 against Impax and several other pharmaceutical companies for unlawfully colluding to fix generic drug prices.

On this news, Impax’s share price fell $4.00, or 19.51%, to close at $16.50 on November 3, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

Go to Source